Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment

Leonie Müller-Jensen; Helene Kriedemann; Kerstin Anvari; Petra Huehnchen; Volker Siffrin

doi:10.1212/WNL.0000000000206743

Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment

Neurology. 2023 Apr 4;100(14):670-671. doi: 10.1212/WNL.0000000000206743. Epub 2022 Dec 20.

Authors

Leonie Müller-Jensen¹, Helene Kriedemann², Kerstin Anvari², Petra Huehnchen², Volker Siffrin²

Affiliations

¹ From the Departments of Neurology (L.M.-J., P.H., V.S.), and Infectious Diseases and Respiratory Medicine (H.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Berlin Institute of Health (P.H., L.M.J.), Charité-Universitätsmedizin Berlin; and private practice (K.A.), Berlin, Germany. [email protected].
² From the Departments of Neurology (L.M.-J., P.H., V.S.), and Infectious Diseases and Respiratory Medicine (H.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Berlin Institute of Health (P.H., L.M.J.), Charité-Universitätsmedizin Berlin; and private practice (K.A.), Berlin, Germany.

Abstract

Fingolimod-induced lymphopenia is a risk factor for severe monkeypox infection. As monkeypox was recently declared a Public Health Emergency of International Concern, vaccination should be evaluated in patients with MS before immunosuppressive treatment, particularly in patients receiving sphingosine-1-phosphate receptor modulators.^,

MeSH terms

Fingolimod Hydrochloride / adverse effects
Humans
Immunosuppressive Agents / adverse effects
Mpox, Monkeypox* / complications
Multiple Sclerosis* / complications
Multiple Sclerosis* / drug therapy
Multiple Sclerosis, Relapsing-Remitting* / complications
Multiple Sclerosis, Relapsing-Remitting* / drug therapy

Substances

Fingolimod Hydrochloride
Immunosuppressive Agents